<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845321</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-9945-101</org_study_id>
    <nct_id>NCT04845321</nct_id>
  </id_info>
  <brief_title>VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers</brief_title>
  <official_title>Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of VNRX-9945 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venatorx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Venatorx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part first-in-human dose-ranging study to evaluate the safety and&#xD;
      pharmacokinetics of escalating doses of VNRX-9945.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part 1, subjects will receive a single dose of VNRX-9945 or placebo. Subjects enrolled in&#xD;
      the food effect cohort will receive a dose in a fasted and fed state (total 2 doses) of&#xD;
      VNRX-9945 or placebo following an appropriate washout period between the doses. In Part 2,&#xD;
      subjects will receive doses of VNRX-9945 or placebo daily for 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of subjects with adverse events</measure>
    <time_frame>Up to 8 days after last administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of subjects with adverse events</measure>
    <time_frame>Up to 8 days after last administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-tau</measure>
    <time_frame>Days 1-6 (Days 1-12 for fasted/fed cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax</measure>
    <time_frame>Days 1-6 (Days 1-12 for fasted/fed cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: tmax</measure>
    <time_frame>Days 1-6 (Days 1-12 for fasted/fed cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUCinf</measure>
    <time_frame>Days 1-6 (Days 1-12 for fasted/fed cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: t1/2</measure>
    <time_frame>Days 1-6 (Days 1-12 for fasted/fed cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC0-tau</measure>
    <time_frame>Day 1 and Following Last Dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax</measure>
    <time_frame>Day 1 and Following Last Dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: tmax</measure>
    <time_frame>Day 1 and Following Last Dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: t1/2</measure>
    <time_frame>Following Last Dose on Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>VNRX-9945</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-9945</intervention_name>
    <description>Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)</description>
    <arm_group_label>VNRX-9945</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for VNRX-9945</intervention_name>
    <description>Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults 18-55 years&#xD;
&#xD;
          2. Males or non-pregnant, non-lactating females&#xD;
&#xD;
          3. Body mass index (BMI) between 18 and 32.0 kg/m2 and total body weight &gt;50 kg (110 lbs)&#xD;
&#xD;
          4. Normal blood pressure&#xD;
&#xD;
          5. Normal lab tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine,&#xD;
             autoimmune, hematologic, neoplastic, or neurological disorder&#xD;
&#xD;
          2. History of severe allergic or anaphylactic reaction&#xD;
&#xD;
          3. Abnormal ECG or history of clinically significant abnormal rhythm disorder&#xD;
&#xD;
          4. Positive alcohol, drug, or tobacco use/test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New Zealand Clinical Research</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

